Detalhe da pesquisa
1.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
N Engl J Med
; 383(14): 1328-1339, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32997907
2.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
3.
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol
; 21(9): 1224-1233, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888454
4.
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC 04-2017).
Future Oncol
; 16(4): 5-10, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31894704
5.
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.
BMC Cancer
; 16: 312, 2016 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27179511
6.
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.
J Am Acad Dermatol
; 74(6): 1077-85, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26946985
7.
Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.
Support Care Cancer
; 24(12): 5007-5014, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27525991
8.
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
Future Oncol
; 11(3): 421-9, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25675123
9.
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
BMC Cancer
; 14: 953, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25511923
10.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol
; 13(3): 239-46, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22285168
11.
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Lung Cancer
; 178: 191-197, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868180
12.
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital.
Front Oncol
; 13: 1104659, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36923436
13.
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
BMC Cancer
; 12: 301, 2012 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22817667
14.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
J Thorac Oncol
; 17(2): 289-308, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34648948
15.
Economic analyses of immune-checkpoint inhibitors to treat lung cancer.
Expert Rev Pharmacoecon Outcomes Res
; 21(3): 365-371, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306411
16.
Two-Stage Bronchoscopic Endobronchial Valve Treatment Can Lead to Progressive Lung Volume Reduction and May Decrease Pneumothorax Risk.
Int J Chron Obstruct Pulmon Dis
; 16: 1957-1965, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34234426
17.
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Lung Cancer
; 161: 122-127, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34583220
18.
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC.
J Thorac Oncol
; 16(11): 1872-1882, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34265434
19.
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis.
Ther Adv Med Oncol
; 13: 17588359211006983, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33948123
20.
Biomarkers in lung oncology.
Pulm Pharmacol Ther
; 23(6): 508-14, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20471486